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ABSTRACT 
 
 
  
 The purpose of this IQP is to compile information regarding the topic of stem cells, and 
then draw conclusions about this new technology and its effects on society.  Stem cells are 
undifferentiated cells with the ability to renew and divide indefinitely to generate specialized 
cells.  The seemingly unlimited potential of stem cell research has several medical applications 
and has founded the new field of regenerative medicine.  However, their use draws strong ethical 
concerns for embryonic type stem cells, which leads to the creation of legislation to dictate the 
boundaries of this new technology.      
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PROJECT OBJECTIVES 
 
 
 The objective of this IQP project was to investigate the controversial topic of stem cells, 
and to discuss the progression of this new technology and its influence on society. The purpose 
of chapter-1 is to define the various types of stem cells, where they are found, and how they can 
be distinguished via potency.  Chapter-2 describes how these stem cells are applied in practical 
experiments that have generated success not only in animal studies but in human clinical trials. 
The purpose of chapter-3 is to confront the moral concerns surrounding this controversial topic, 
while chapter-4 dives into U.S. and international laws that govern this growing field.  Finally, the 
author‘s conclusions are discussed based on the research gathered for this project. 
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CHAPTER-1:  STEM CELL TYPES 
 
Thomas Fontecchio 
 
 
 
Stem cells are the foundation for every organ, tissue, and cell in the body. Stem cells are 
a class of undifferentiated cells that are able to differentiate into a specific cell type. The major 
function of stem cells is to maintain homeostasis in the body in terms of replacing dead or 
injured cells with new ones that function properly. A common misconception is grouping stem 
cells into one large category even though there are a number of different types. When stem cells 
are brought up in conversation, most people associate the term with the infamous embryonic 
stem cells, but not all stem cells are the same and some are far less controversial than others. 
Recent advances in technology and science have provided health care professionals with new 
opportunities and alternatives to conventional techniques that only treat the symptoms of a 
disease or injury. These cells have the ability to continuously multiply and develop into various 
types of cells in the body founding the new field of ―regenerative medicine‖.  The purpose of this 
chapter is to document the various types of stem cells and to lay the foundation for our later 
chapter discussions on their ethics and legalities. 
 
Stem Cell Potency  
The primary defining feature of a stem cell is potency, or its ability to become other cell 
types.  Stem cells divide asymetrically, producing one cell that retains the ability to divide 
indefinitely and another cell that is more specialized than the first.  The function of the 
indefinitely dividing population is to serve as a reservoir of long lived cells, while the more 
differentiated cells replace damaged or aging tissues.  The less potent a stem cell is, the fewer 
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tissues it can form. There are four varying degrees of potency.   Totipotency is the ability of a 
cell to produce all the differentiated cells that form an entire organism, plus the extra-embryonic 
tissue such as the placenta. Newly fertilized eggs are totipotent.  As the cells of the embryo begin 
dividing, the cells through the embryo 8-cell stage (48 hrs) also remain totipotent, but not 
thereafter.  Embryonic stem cells (ESCs) constitute the inner cell mass of the 5-day old 
blastocyst, and are termed pluripotent because they have the ability to differentiate into any of 
the three germ layers (endoderm, mesoderm, and ectoderm), and can give rise to any adult tissue. 
Multipotent cells can form multiple related types of cells, but with a limited number of lineages. 
An example of multipotent stem cells are hematopoietic stem cells that can develop into several 
types of blood and marrow cells, but which normally lack the ability to develop into brain or 
nerve cells.  Stem cells which are almost fully differentiated are known as unipotent cells, which 
are locked into specific cell fates, depending on the tissue origin. 
 
Stem Cell Background  
Recent developments in stem cell research have been considered breakthroughs for 
science and the field of biology, so with all the press coverage and ethical debates, the layperson 
might think stem cells are a recent discovery.  Stem cell work actually has a long history that 
dates back to the late 1800s.   In 1886, William Sedgwick used the term ―stem cell‖ to describe 
the regenerative properties of plants (Chamany , 2004).  A decade later, E.B. Wilson applied the 
term to cells in the roundworm that retained genetic material and appeared to regenerate. 
Contemporary stem cell techniques also arose from embryology work of the late 1800s and early 
1900s.  In 1912, Jacques Loeb successfully achieved artificial parthenogenesis, the process by 
which unfertilized eggs undergo chromosome duplication and rapid mitosis to establish a 
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developing embryo (Chamany , 2004).  Loeb subjected sea urchin eggs to various concentrations of 
salt, stimulating them to undergo cell division as if sperm had fertilized them. The ability to 
induce an organism that does not naturally reproduce via parthenogenesis was groundbreaking. 
The work was heralded in newspaper headlines as ―The Creation of Life‖, and made accessible 
to the public through literature. 
More recently in the 1950‘s and 1960‘s, in vitro fertilization (IVF) techniques were 
developed for animals, and were later applied to humans in IVF clinics in the late 1960‘s (Deech, 
2008).  IVF clinics provided a boost to stem cell knowledge from the research performed with 
extra discarded embryos that were not reimplanted for reproductive purposes, eventually leading 
in 1998 to the isolation and growth of human ESCs from 5 day old blastocysts (Thomson et al., 
1998).   The use of embryos in research has always been a topic of ethical debate, and will be 
discussed in detail in Chapter-3. 
 
Embryonic Stem Cells  
With the discovery of IVF, scientists were able to study the developmental pathways 
beyond the first stages of embryogenesis and chart the fate of each cell in the developing 
organism. It was established that all adult cells arise from three primary germ layers: the 
endoderm, mesoderm, and ectoderm.  These cell layers arise early in embryonic development 
about day-5 when a cavity called the archenteron forms the blastula. The blastula (Figure-1) is a 
hollow ball of cells consisting of the inner cell mass (ICM) which contains ES cells and forms 
the embryo, and the trophoectoderm which forms the placenta.  The ICM over time reorganizes 
into the three primary germ layers. 
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Figure-1:  Photograph of a Human Blastocyst at Day-5.  The cells of the 
inner cell mass (ICM) contain ES cells, and eventually become the embryo.  The 
cavity or blastocoel is marked with a C.  The outer layer is the trophoectoderm 
that will form the placenta.   (Advanced Fertility Center, 2007) 
 
The endoderm is the first embryonic layer to form, and begins in the human embryo at 
about two weeks after fertilization. By the fifth week, the endoderm will differentiate into 
internal structures such as the liver or pancreas. The mesoderm is the next layer to grow.  From 
the mesoderm comes the intermediate organs such as muscle, bone, connective tissue, and the 
reproductive and urinary systems. The ectoderm is the final germ layer to form, and consists of 
three separate parts: surface ectoderm, neural ectoderm, and neural crest. The surface ectoderm is 
responsible for developing skin and other tissue such as eyelid epidermis, tooth enamel, and the 
mucous membrane of the mouth. The neural ectoderm acts to form the retina, optic nerve fibers, 
and retinal pigment. This part of the ectoderm contains the neural tube, which is responsible for 
developing the central nervous system. The cells in the neural crest develop into parts of the 
skeletal system, autonomic nervous system, and produce hormones (Shiraki et al., 2009).  
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A fourth set of embryonic cells specifically give rise to the reproductive organs and are 
called the primordial germ cells (PGCs).  During the 1950‘s and 1960‘s, work by cancer 
specialist Leroy Stevens first suggested that some of these PGC cells might be pluripotent and 
that surrounding cells provide the necessary environmental signal needed to stimulate 
differentiation (Chamany , 2004).  Stevens conducted a series of experiments and found that such 
cells exist and share similar characteristics with cancer cells. Stevens came across some cells 
which originate from primordial germ cells and found that they formed teratomas. A teratoma is 
an encapsulated tumor with tissue or organ components resembling normal derivatives of all 
three germ layers (Baker, 2009).  PGCs normally go on to develop into the cells of the ovaries or 
the testes in the adult organism, but some cells maintain the capacity to become a variety of cell 
types, and others can become malignant which develop into tumors. Stevens decided to conduct 
an experiment with early embryonic cells from the inner cell mass and found that they went on to 
develop into teratomas upon injection into mice testes. With this discovery came the name 
embryonal carcinoma cells (ECs), which is another name for a type of germ cell tumor that 
forms in the ovaries and testes.    
In 1981, two research groups advanced the field of developmental biology one step 
further when they successfully established animal embryonic cell lines. The ES cells could now 
propagate indefinitely in vitro to provide more cells for analysis.  Martin Evans and Matthew 
Kaufman at Cambridge University were able to culture mouse ES cells from blastocysts using a 
medium conditioned by the cell lines established by Stevens (Evans and Kauffman, 1981). They 
also demonstrated that these ES cells spontaneously differentiated into a variety of cell types 
when injected into an adult mouse. 
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In the late 1980s, Brigid Hogan, Peter Donovan, and researchers at the Ludwig Institute 
for Cancer Research in Australia identified a specific factor and cell culturing technique in which 
mouse ES cells can propagate and maintain an undifferentiated state (Chamany, 2004). This 
work led to a more thorough understanding of how protein concentration, timing, and cell fates 
are related.  Researchers now understand that each ESC has intrinsic genetic programming or the 
potential to become any cell of the adult. Extracellular proteins were understood as the extrinsic 
factors that provide the necessary signals to promote differentiation into one cell type versus 
another.   The animal ES cell work continued into the 1990s, and in 1998 the first human 
embryonic stem cells (hESCs) were isolated.  
 
Human Embryonic Stem Cells 
Human embryonic stem cells (hESCs) are derived from embryos at a developmental 
stage before the time that implantation would normally occur in the uterus. Fertilization normally 
occurs in the oviduct, and during the next few days, a series of cleavage divisions occur as the 
embryo travels down the oviduct and into the uterus (Regenerative Medicine, 2006). The first 
differentiation event in humans occurs around five days of development when an outer layer of 
cells committed to becoming part of the placenta separates from the inner cell mass (ICM) 
(Regenerative Medicine, 2006). The ICM form a cluster of identical totipotent cells known as 
blastomeres but after implantation, they are quickly depleted as they differentiate to other cell 
types with limited developmental potential. However, if the ICM is removed from its normal 
embryonic environment and cultured under appropriate conditions (Figure-2), the ICM-derived 
cells can continue to proliferate and replicate themselves indefinitely and still maintain the 
development potential to form any cell type of the body.  
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Figure-2: Diagram of Human ES Cell Isolation.   ES cells of the 
blastocyst inner cell mass (blue), are isolated from day-5 
blastocysts (diagram center) and grown on feeder cells (diagram 
lower) that provide a scaffold and growth factors.  (Regenerative 
Medicine, 2006) 
 
  
 
 
 
 
 
 
In 1998, human ES cell lines were derived from embryos produced by in vitro 
fertilization (IVF), a process in which egg and sperm are placed together to allow fertilization to 
take place in a culture dish (Thomson et al., 1998). Clinics use IVF to treat certain types of 
infertility, and sometimes, during the course of these treatments, embryos are produced that are 
no longer needed by the couples for producing children. Each year, hundreds of thousands of 
poor-quality embryos are regularly discarded during the course of IVF, and these could provide a 
source of stem cells for research. Unfortunately, the process of gathering ES cells from the ICM 
inevitably involves the destruction of the embryo which is of significant ethical concern. The 
intentional creation and destruction of emerging human life raises serious ethical, religious, legal 
and political concerns that will be discussed in greater detail in later chapters. However, there are 
a number of approaches that may allow for the derivation of pluripotent cells that do not involve 
the generation and destruction of a viable human embryo.  
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Induced Pluripotent Stem Cells (iPSCs) 
Induced pluripotent stem (iPS) cells are a type of pluripotent cell artificially derived from 
a non-pluripotent cell by inducing a forced expression of specific genes. iPSCs were first 
generated by Shinya Yamanaka‘s team at Kyoto University, Japan in 2006 for mouse cells 
(Yamanaka, 2007) and later in a landmark article for human cells (Takahashi et al., 2007). 
Yamanaka used genes encoding proteins as particularly important in ES cells, and used 
retroviruses to transfect those genes into mouse fibroblasts with a selection of those genes. This 
approach identified four key pluripotency genes essential for iPS cell production; Oct-3/4, 
SOX2, c-Myc, and Klf4 (Yamanaka, 2007).  However, this initial iPS cell line showed errors in 
DNA methylation compared to original patterns in ES cell lines. In June 2007, the same group 
published a breakthrough study along with two other independent research groups from Harvard, 
MIT, and UCLA showing successful reprogramming of mouse fibroblasts into iPS cells.  
In November of that same year, two independent research teams created iPSCs from adult 
human cells, laying the groundwork for the potential evolution of stem cell research and it‘s 
regenerative application in humans. The two studies released were Science by James Thomson at 
the University of Wisconsin-Madison (Yu et al., 2007), and the other in Cell by Shinya 
Yamanaka and colleagues at Kyoto University, Japan (Takahashi et al., 2007). The same 
principles used earlier in the mouse models were used again for the human work, and human 
fibroblasts were successfully transformed into pluripotent stem cells using the same four pivotal 
genes with a retroviral system. The viral transfection system used to insert the genes at random 
locations in the host‘s genome created concern for potential therapeutic applications of these 
iPSC‘s, because the created cells might be prone to form tumors (Yamanaka, 2007).  So in May 
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of 2009, a team of scientists generated human iPS cells by direct delivery of the proteins, thus 
eliminating the need for viruses or genetic modification.  
Based on current research, iPSCs appear to be similar to natural pluripotent stem cells, 
with respect to the expression of specific stem cell genes and proteins, chromatin methylation 
patterns, cell doubling time, embryoid body formation, teratoma formation, and potency and 
differentiability (Baker, 2009).  However, more recent research indicates iPS cells may divide 
slower and are less robust than true ES cells (Dolgin, 2010).  But even if iPS cells eventually 
prove slightly less potent than ES cells, so long as they can be grown in culture they might serve 
as an excellent replacement for IVF-derived ES cells.  This is an important advance in stem cell 
research because it may allow researchers to obtain pluripotent stem cells without the added 
controversy of using embryos. There is also a chance that these cells are less prone to immune 
rejection than ES cells because they are derived entirely from the same patient.  
  
Parthenogenetic ES Cells  
Parthenogenesis is the process by which an egg can develop without the presence of the 
male counterpart. It is a form of asexual reproduction common in a variety of organisms such as 
fish, ants, flies, honeybees, amphibians, and lizards and snakes that may routinely reproduce in 
this manner. Mammals are not naturally capable of this form of reproduction, however 
mammalian oocytes (eggs) can successfully undergo artificial parthenogenesis in vitro by 
mimicking the calcium wave induced by sperm during normal fertilization which causes cell 
stimulation and division (Berevini, 2008). Parthenogenetic embryos can develop to the blastocyst 
stage, and so could serve as a source of ES cells. Mouse parthenogenetic ESCs (pESCs) have 
been shown to have the properties of self-renewal and the capacity to generate cell derivatives of 
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the three germ layers, confirmed by contributions to chimeric animals and/or teratoma formation 
when injected into mice. Moreover, the cells do not involve the union of male and female and so 
genetic material will be derived exclusively from the female oocyte donor. This technique is 
advantageous because using a woman‘s own egg to create stem cells almost guarantees a 
complete genetic match for use in that same woman with a low risk of rejection. However, the 
genetic match is not perfect, as each egg is created with a slightly modified set of genes due to 
imprinting, the cell‘s way of chemically modifying DNA in the genome. Imprinting can silence 
some essential genes for reproduction and growth because the genes of the opposite sex are not 
properly expressed.  pESCs have been successfully derived from primate parthenote embryos 
(Cibelli et al., 2002) but not yet from human eggs. 
 
Adult Stem Cells 
 An adult stem cell (ASC) is a rare undifferentiated cell found among differentiated cells 
in tissues or organs that have already been developed.  ASCs can differentiate to yield some or 
all of the major specialized cell types of that tissue or organ. The primary roles of ASCs are to 
maintain and repair the tissue in which they are found.  The term ―adult‖ does not refer to the age 
of the organism, only that it is observed in organisms later than the embryonic stage. Unlike ES 
cells, which are defined by their origin in the inner cell mass of the blastocyst, the origin of adult 
stem cells in some mature tissue is still under investigation. ASCs have been identified in many 
organs and tissues, including brain, bone marrow, peripheral blood, blood vessels, skeletal 
muscle, skin, teeth, heart, gut, liver, ovarian epithelium, and testis.  They are thought to reside in 
a specific area of each tissue called a ―stem cell niche‖ where they remain inactive for long 
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periods of time until they are activated by a need to maintain tissue whether caused by disease or 
injury.   
 Research on ASCs has generated a great deal of excitement, as these cells may represent 
alternatives to ES cells, although they are lesss potent, and are harder to isolate and grow.  The 
history of research on ASCs dates back to the 1950‘s when researchers discovered that bone 
marrow contains at least two types of stem cells (NIH Stem Cell Information, 2006). One 
population, called hematopoietic stem cells (HSCs), forms all the types of blood cells in the 
body. The second population, called mesenchymal stem cells (MSCs) was discovered a few 
years later, and make up a small proportion of the stromal cell population in the bone marrow.  
MSCs can generate bone, cartilage, and fat cells that support the formation of blood and fibrous 
connective tissue.  
 
Hematopoietic Stem Cells (HSCs) 
HSCs are multipotent stem cells that give rise to all the blood cell types. This is no small 
task considering the average human body goes through around 100 billion hematopoietic cells 
every day.  The most prominent application of stem cell research has been bone marrow 
transplants using HSCs.  In the early 1900‘s, physicians administered bone marrow by mouth to 
patients with anemia and leukemia. Although such oral therapies were unsuccessful, other 
experiments eventually demonstrated that mice with defective marrow could be restored to 
health using infusions into the blood stream of marrow taken from other mice. This caused 
physicians to speculate whether it was feasible to transplant bone marrow from one human to 
another.  In 1958, Jean Dausset identified the first of many human histocompatibility antigens. 
These proteins, found on the surface of most cells in the body, are called human leukocyte 
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antigens, or HLA antigens.  These HLA antigens give the body‘s immune system the ability to 
determine what belongs in the body and what does not. Whenever the body does not recognize 
the series of antigens on the cell surface, it creates antibodies and other substances to destroy the 
cell. A bone marrow transplant between identical twins guarantees complete HLA compatibility 
between donor and recipient. These were the first kinds of transplants performed in humans 
(Abbott, 2003).  
Compared to adult stem cells from other tissues, HSCs are fairly easy to obtain and can 
be found in the three main sources; bone marrow, peripheral blood, and umbilical cord blood. 
Bone marrow is the place where HSCs were first discovered, and it is the location where both the 
majority of the human body‘s HSCs are found, as well as the most commonly used source. There 
is a relatively high concentration of HSCs in most bone marrow that can be used therapeutically 
without the need of further isolation. However, extraction of bone marrow requires a large needle 
and can be a very painful procedure. The second source is peripheral blood that runs throughout 
your arteries and veins, which is much easier to collect than bone marrow. However, the 
concentration of HSCs in peripheral blood is much smaller, so scientists have been able to 
increase this concentration by a process known as ―cytokine mobilization‖ (NIH, 2006).  The 
donor is treated with cytokine hormones to mobilize HSCs from the marrow into the peripheral 
blood.  The last source of HSCs is umbilical cord blood, as well as the placenta, and both are 
usually discarded during childbirth even though HSCs are prevalent. Some hospitals allow the 
mother to freeze the umbilical cord blood and store it at a blood bank in the event of family 
blood problems. Cord blood is generally considered to be better at self-renewal than HSCs taken 
from an adult, and this type also displays fewer transplant rejections (Viacell, 2006).  
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Mesenchymal Stem Cells (MSCs) 
Mesenchymal stem cells (MSCs) are another well-characterized population of adult stem 
cells that are also found in the bone marrow. MSCs are cells that can be cultured and 
differentiate into a large range of tissue including fat cells, cartilage, bone, tendon and ligaments, 
muscle, skin, and even nerve cells. In the bone marrow it forms stroma, which is the architecture 
that hematopoietic stem cells are grown in. Though they exist in a similar concentration in the 
bone marrow, MSCs are much easier to isolate than HSCs because they readily stick to certain 
types of plastic and can propagate easily in a culture medium.  
The presence of non-hematopoietic stem cells in bone marrow was first suggested by the 
observations of the German pathologist Cohnheim. His work raised the possibility that bone 
marrow may be the source of fibroblasts that deposit collagen fibers as part of the normal process 
of wound repair.  Friedenstein and his colleagues began the work of studying bone marrow 
contents that could differentiate into other mesenchymal cells, as well as fibroblasts (Nardi, 2006). 
They placed whole bone marrow in plastic culture dishes and removed the nonadherent cells 
after 4 hours, thus discarding most of the hematopoietic cells. They reported that the adherent 
cells were heterogeneous in appearance and formed two to four types of cells. These cells 
remained inactive for 2-4 days and then began to multiply rapidly.  They also found that these 
cells could differentiate into colonies that resembled small deposits of bone or cartilage. 
Friedensteins‘s observations were exteneded by other groups throughout the 1980‘s, and it was 
established that the isolated cells were multipotent. In test runs on mice infected with gastric 
ulcers, MSCs were observed to migrate from bone marrow to the ulcer and differentiate into 
gastric cells. MSCs have also been observed to contribute to cardiac cells, pancreatic and liver 
cells, and even neural cells. Unlike most other human adult stem cells, MSCs can be easily 
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obtained in quantities appropriate for clinical applications, making them good candidates for use 
in tissue repair. Techniques for their isolation and propagation for long periods of time without 
losing their capacity to form numerous cell types have been established.     
  
Neural Stem Cells (NSCs) 
In the past, most treatments for damage to the brain or spinal cord aim to relieve 
symptoms and limit further damage. Recent research into the regeneration mechanism of the 
central nervous system, including the discovery of stem cells in the adult brain, has raised hopes 
that researchers can find ways to actually repair the damage. In the mid-1990s, neuroscientists 
learned that some parts of the adult human brain do, in fact, generate new neurons under certain 
circumstances. They found that these neurons arise from ―neural stem cells‖ in the adult brain. 
Stem cells in the adult brain occur in two locations; the subventricular zone which is an area 
under fluid-filled spaces called ventricles, and the dentate gyrus of the hippocampus (NIH, 
2006). These two areas of the brain along with areas in the spinal cord contain dividing cells that 
ultimately become nerve cells. Researchers showed in the mid 1990s that when the brain is 
injured, stem cells in these two areas proliferate and migrate toward the site of the damaged 
tissue.  These undifferentiated cells resemble cells in a developing fetus that give rise to the brain 
and spinal cord.  
 NSCs are tripotent, they can form the neurons which make up the brain and nervous 
system, as well as glia and oligodendrocytes. Glial precursors give rise to astrocytes and 
oligodendrocytes. Astrocytes make up to 80 percent of the cells in the adult brain, and lend both 
mechanical and metabolic support for neurons. Oligodendrocytes create myelin, the fatty 
material that ensheathes nerve cell axons and functions to speed nerve transmission (NIH, 2006). 
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NSCs have been isolated and cultured since 2001, and are only found in a few areas in the brain. 
The reason why NSCs have been so difficult to find relative to the other forms of adult stem cells 
is their inactivity. NSCs do not produce very many new neurons in normal activity so extensive 
research is dedicated to figure out why this is and how to stimulate their activity.    
 
Cardiac Stem Cells (CSCs) 
For twenty years or so, scientists have debated whether the human heart can repair itself 
by regenerating new tissue after injury such as a heart attack. New research strongly suggests 
that the heart maintains a reservoir of adult stem cells that enable the heart to make new cells 
when it is damaged. Human cardiac stem cells (hCSCs) are self-renewing, clonogenic, and 
multipotent.  hCSCs differentiate predominantly into cardiomyocytes and, to a lesser extent, into 
smooth muscle cells and endothelial cells (NIH, 2006). Researchers have identified pockets of 
stem cells in the interstices, or spaces, between muscle cells in the hearts of rats. When the stem 
cells were cultured and injected into rats with damaged heart tissue, 70 percent of the damaged 
myocardium was reconstituted within 20 days. Researchers also found similar cells in humans by 
examining tissue from patients with heart disease who underwent cardiac surgery. It appeared 
that the accumulated stem cells had been attempting to repair the damaged heart. The space 
where these cells reside has been identified, and the next step is to determine how to mobilize the 
cells to regenerate and proliferate. Researchers are spending considerable effort to stimulating 
cardiac stem cells already living in the heart to grow without surgical implantation. For years the 
general belief has been that the number of cells in the heart was established at birth. Now it is 
understood that the heart could not contract for so many years using the same cells, and that a 
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pool of stem cells is needed to repair any damaged tissue. There is still a lot to be learned about 
the biological mechanism that turns these cells on and off.    
 
Epithelial Stem Cells (ESCs) 
Most, if not all, epithelial tissues contain stem cells. They are responsible for normal 
tissue renewal and replacement after damage. With certain exceptions, epithelial stem cells are 
considered to be developmentally committed such that they can form the differentiated cells of 
their own particular tissue type, but not those of any other tissue.  Our present knowledge of their 
properties is limited and is mainly derived from studies of cell kinetics and from clonal analysis. 
About 60% of the differentiated tissue types in a mammalian body are epithelia. Most epithelial 
tissues self-renew throughout adult life due to the presence of multipotent stem cells and/or 
unipotent progenitor cells (Blanpain, 2007). Epithelial stem cells are specified during 
development, and are controlled by epithelial-mesenchymal interactions. Despite morphological 
and functional differences among epithelia, common signaling pathways appear to control 
epithelial stem cell maintenance, activation, lineage determination, and differentiation. However, 
a deeper understanding of these regulatory pathways must be gained, as their deregulation can 
lead to human disorders including cancer.  
 
Chapter-1 Conclusion 
 Twenty years ago, if you told a biologist that we were a few decades away from being 
able to regrow entire organs, you probably would have been laughed at. This idea of regeneration 
solely occupied the realm of science fiction but today it is considered an inevitable reality. Stem 
cells are the building blocks for every living cell in our body and as technology advances so too 
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will the practicality of this field. The controversy surrounding embryonic stem cells has bogged 
down research for many years, focusing on the legal and moral issue of destroying a life. This 
debate has also been detrimental to the field in more ways than one. The argument over 
embryonic stem cells has created a negative stigma that associates all stem cells to the current 
issue at hand. As societies‘ knowledge of stem cells progresses, alternatives to the current moral 
dilemma will arise as well as innovative techniques for isolating, growing, and applying these 
cells.   
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CHAPTER-2:  STEM CELL APPLICATIONS 
Brandon Cooney 
 
 
Numerous diseases worldwide currently have no cure.   But fortunately, treatments for 
some of them my lie with stem cells and the new field of regenerative medicine.  Since stem 
cells have the ability to renew themselves and form various types of cells, the hope is to use them 
to replace aged or damaged tissues.  But for the most part, this new field of medicine is relatively 
unexplored, leaving some stem cell applications as hopes for the future.   And for embryonic 
stem cells, some people deem their use as unethical.  The purpose of this chapter is to help 
document the benefit to society of some stem cell applications, as the benefits weigh will heavily 
in our ethical discussions of Chapter-3.  Some applications have already been used successfully 
for 50 years now (bone marrow transplants), while other applications remain ―pie in the sky‖.  
This chapter will show how stem cells can be applied to help people diagnosed with certain 
illnesses, to inform the reader of the great potential of this area of medicine, before discussing 
the ethics and legalities behind stem cells in later chapters. 
 
Fanconi’s Anemia 
 Fanconi‘s anemia is a genetic disorder that occurs in 1 of every 350,000 births, and 
occurs more frequently in Afrikaans in South Africa and Ashkenaze Jews  (Moustacci, 2003).  
There are seven different mutations of Fanconi‘s in genes encoding proteins that are responsible 
for DNA repair.  As a result of this, over 20% of Fanconi‘s anemia patients develop a form of 
cancer, and 90% develop bone marrow failure by 40 years old.  The life expectancy of someone 
diagnosed with Fanconi‘s anemia is 30 years.  At this time, there is no cure for Fanconi‘s, but 
 25 
there are ways to make it more bearable and give the patient a better chance at surviving.  The 
first option is to do androgen therapy and hematopoietic growth factor therapy.  But not all 
patients respond to this protein supplement treatment and it is temporary.  The best treatment is a 
hematopoietic stem cell transplation.   
 As described in the previous chapter, hematopoietic stem cells (HSCs) are multipotent 
stem cells that give rise to all of the various types of blood cells.  Because HSCs have been used 
for 50 years in bone marrow transplants to treat blood disorders (Thomas et al., 1957), they 
represent the most characterized of all the stem cells.  According to a study done in Paris in 
2000, allogeneic stem cell transplantation is the only treatment that can cure a Fanconi‘s anemia 
patient.  But to increase the odds that the transplant will not be rejected, HLA typing must be 
done, and the odds of finding a compatible donor are low.   
 One future application would be to use histocompatible embryonic stem (ES) cells to 
treat the anemia.  In this procedure, the parents would create embryos by in vitro fertilization 
(IVF), grow them 5 days to the blastocyst stage, then isolate ES cell lines.  These ES cell lines 
should have a high likelihood of being histocompatible as they would represent ―siblings‖ of the 
anemia patient (Grewal et al., 2004). 
 But one downside to using stem cells is the formation of cancer in some patients.  There 
is a significantly higher chance (4.4 times more likely) for a Fanconi patient to get squamous cell 
cancers (SCC) in the head, neck, and esophagus after the transplantation (Rosenberg et al., 
2005).  And the people who receive the transplantation are diagnosed with SCC at a much earlier 
age than those without the transplant (median age of 18 and 33, respectively).  The chance of 
SCC survival is very slim.  So Fanconi‘s anemia serves as an example of a stem cell application 
in which hundreds of lives have already been saved, even if a small percent get cancer from the 
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treatment.  Scientists are currently working on understanding why some stem cells form cancer, 
and how to prevent it from happening.  
 Another promising stem cell approach to Fanconi‘s anemia is to treat the patient‘s own 
iPS cells.  In this approach, a patient‘s skin cell is treated with transcription factors to de-
differentiate it to an ES-like state.  The ES cells are genetically identical to the patient, so are less 
likely to be rejected.  This approach has worked in vitro to derive the cells, but has yet to be 
applied to anemia patients (Delgado, 2009). The current research being done on this new strategy 
for helping patients with Fanconi‘s anemia is only at the preclinical level, but is showing signs of 
hope.  The hope is that these iPS cells will not cause tumors, like ES cells can (Delgado, 2009.) 
 
Parkinson’s Disease 
 Parkinson‘s disease (PD) is the most prevalent disorder of the central nervous system.  
PD causes impaired motor skills, and difficulty initiating other seemingly routine functions.  The 
primary symptoms of PD are bradykinesia, tremors, rigidity, and poor balance (HelpGuide.org, 
2010).  Bradykinesia is slowness in voluntary movements, such as sitting and standing.  Tremors 
most often occur in the hands, fingers, and feet when the limbs are at rest.  Almost all of PD 
symptoms are caused by the loss of dopamine producing cells in the brain.  Dopamine is a 
neurotransmitter used by the brain to perform muscle movements.  In the United States alone, 
50,000 new people are diagnosed annually with PD.   
 Since 1998, stem cells have been used in rat models of PD as a possible treatment.  Rat 
models have shown improved symptoms when treated with adult neuronal stem cells (NSCs) 
(Studer et al., 1998), with embryonic stem (ES) cells (Bjorklund et al., 2002; Kim et al., 2002; 
Ryan, 2004), or with NSCs derived in vitro from ES cells (Ben-Hur et al., 2004).   
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Monkey stem cell trials were done in Georgia in 2006.  In this study, researchers 
compared the difference in the animals that received a placebo versus those that received an 
adult neural stem cell transplant, or received protective neurotrophic factors secreted by stem 
cells (Science Daily, 2006).  Although most of these trials were done in animals with very early 
stages of Parkinson‘s, the results were good.  The animals that received the stem cell transplants 
regained control over their motor skills, and after a month when the researchers re-examined the 
monkey‘s brain, the transplanted cells had survived and formed synapses in the part of the brain 
that creates the dopamine.  The monkeys that received no treatment did not recover, and the ones 
that received the NTF treatment, partially recovered (Science Daily, 2006). 
 With respect to treating human PD patients, some early successes were obtained by 
transplanting fetal brain tissue (Madrazo et al., 1988; Lindvall et al., 1989; Freed et al., 2001, 
Mendez et al., 2002), but fetal tissue is even more controversial than ES cells as it is obtained 
from aborted tissue.  One study reported the successful treatment of a human PD patient by 
transplanting adult olfactory mucosal stem cells (Levesque, 2005).  With respect to human ES 
cells, these cells have been shown to be capable of differentiating into dopamine-producing cells 
in vitro (Perrier et al., 2004).  
In 2009, a team of UCLA researchers published their findings, saying ―we have 
documented the first successful adult neural stem cell transplantation to reverse the effects of 
Parkinson's disease, and demonstrated the long term safety and therapeutic effects of this 
approach," said lead author Dr. Michel Levesque (Ertelt, 2009).  The research team was only 
able to have one PD patient for this initial trial, but their patient‘s motor skills significantly 
improved.  Prior to this trial, the lab reported their ES cells were rejected.  The biggest points 
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made by the researchers is that their approach using adult NSCs does not use the more 
controversial ES cells, nor did it produce any cancers. 
 
Rheumatoid Arthritis 
 Rheumatoid arthritis (RA) is a systemic inflammatory disorder that can cause damage to 
various tissues, organs, and joints.  It is a disease that affects 1% of the world‘s population.  RA 
is far more prevalent in women than in men, and normally begins about age 40-50.  The disorder 
can be a very painful condition that can lead to a significant loss in the patient‘s ability to 
function.  Currently, various treatments suppress the symptoms and make the disorder more 
bearable, but there are no cures. 
 In The Netherlands, researchers have conducted a study in which they found a new 
therapy option for RA, high dose chemotherapy followed by HSC transplantation (Teng et al., 
2005).  Similarly, a study was conducted in Australia in 1998, in which stem cells derived from 
bone marrow were given to 3 patients (Snowden et al., 1998).  This method of treatment was so 
successful, it was dubbed as a potential RA cure.   As the result of these studies, 76 patients with 
RA were signed up for a study.  Of these patients, 73 received HSC transplantations, and of all of 
the patients after 12 months had an ACR score (American College of Rheumatology criteria) of 
less than 50% (Snowden, 2004).  There were also cases tested with sibling HSC transplants, in 
which the treatment helped lower the symptoms of RA in a 52 year old woman (Nowak, 2004).  
She originally had arthritis in 28 of her joints, and the treatment helped her rid morning stiffness 
and aches and pains that all RA patients have (Nowak, 2004). 
 Mesenchymal stem cells (MSCs) from the umbilical cord have recently been used to help 
treat various diseases, including RA (SCT, 2010).  And there is current speculation that 
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providing cord HSCs could help reduce the risk in cardiovascular disease along with reducing 
damages done to the joints from RA.  
  
Cardiovascular Disease 
 Cardiovascular disease affects the heart and blood vessels, and is the number one cause 
of death in the United States.  The four most common types of cardiovascular diseases are high 
blood pressure, stroke, coronary heart disease, and heart failure.  Cardiovascular diseases 
claimed 1 in every 2.9 deaths in 2006  (American Heart Association, 2006).  The main cause of 
cardiovascular disease is the build of plaque in the heart and circulatory system, as the result of 
unhealthy eating, lack of exercise, or smoking. 
 With respect to stem cell treatments, the heart does not normally have the ability to fix 
itself from large scale damage, so using stem cells could provide an answer to this problem.  In 
the heart, there are three different types of cells: myocytes, vascular endothelial cells, and 
smooth muscle cells (Semsarian, 2002).  Injecting myocytes does not appear to work well as they 
usually fail to integrate into the existing tissue (Goldthwaite, 2006), but injecting heart stem cells 
has shown some success in animal models.   
 On June 26, 2009, the first FDA-approved human phase-I clinical trial in the United 
States was completed using heart stem cells (Medical News Today, 2009).  In the procedure, 
they took the patient‘s own heart tissue, used it to isolate and grow the heart stem cells, and 
injected those stem cells back into the patient‘s heart.  In the phase-I trial, there are 24 patients 
who have had heart attacks, and who will undergo the stem cell procedure.  
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Chapter-2 Conclusion 
 This chapter shows some of the medical success stories with stem cells as an example of 
their benefits to society.  Although some stem cell treatments are more advanced than others, the 
new science has the potential to revolutionize medicine.  But beyond their benefits lie medical 
and legal concerns, which will be the subject of the next chapters.  With the regenerative 
properties of stem cells, there seems to be no ceiling for the good that might come from further 
research in regenerative medicine. 
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Chapter-3: Stem Cell Ethics 
 
Thomas Izzo 
 
 
Chapter Introduction 
 
 The first two chapters described the different types of stem cells and the applications for 
which they are used. We now turn our attention to the topic of whether these cells should be 
used.  Human ethics is a crucial side of the stem cell discussion. Ethics is a philosophy of 
morality within a person, guiding them on how to conduct life and act. Stem cells touch on ethics 
in several different ways, including topics such as: when does human life begin, should human 
cloning be allowed, or should one potential life be sacrificed to save another?  In theory, stem 
cells are an amazing tool for scientists to use to heal and save lives. Their value lies in the ability 
to create nearly every cell type in the body.  But, has this research gone too far, and has it 
crossed the boundary of moral limits?  Ethics is incorporated in the stem cell debate in this 
chapter as an example of the impact of technology on society.   
Many people form personal opinions on stem cells while being unaware that stem cells 
are not all alike.  Each type has its own ethical dilemmas.  As discussed in Chapter-1, embryonic 
stem (ES) cells are the most debated form of stem cell, as an embryo is destroyed to obtain them.  
ES cells are extracted from the inner cell mass of five day old blastocysts formed by in vitro 
fertilization (IVF).  If one believes that life begins at conception, then destroying a five day old 
embryo might be considered murder.  So is the life of the embryo more valuable than the life of 
say a three year old girl?  But, if one believes that life begins later in development, say at time of 
embryo implantation or at the time of birth, one would have fewer issues with destroying an 
embryo to save other lives.  Or perhaps one can view the embryo as potential life, because the 
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embryo must be implanted into the uterus to form a fetus, so does potential life have a different 
moral status than a living person?  Is murder worth healing others? 
 Adult stem cells (ASCs) are obtained from adult tissues.  These cells come from teeth, 
umbilical cords, blood, bone marrow, skin, brain, etc.  Obtaining them does not destroy an 
embryo.  ASCs are programmed to repair a specific damaged tissue in the body, and are being 
used to treat more than seventy types of pathology conditions today, including several types of 
cancers and blood disorders.  Using ASCs does not destroy the embryo, and the practice is 
accepted by all major religions.  ―Adult stem cells - do not have the potential to become any cell 
of the body. They are still called stem cells because they have the potential to become other cells, 
but their trajectory is limited to a small number of cell types‖ (Hinman, 2004) This is the drawback 
with using adult stem cells because they have a limited number of applications; they do not grow 
as well as ES cells and they are not as medically potent.  
Somatic cell nuclear transfer (SCNT), also known as therapeutic cloning, is the process 
by which the nucleus of an egg cell is removed and is replaced with the nucleus of a skin cell.  
The egg then receives an electric shock and begins to divide. The dividing cells form a blastocyst 
after three to five days, from which ES cells can be extracted.  SCNT has been successful with 
mice, but not yet in humans (Memorial Sloan-Kettering, 2008).  Using this process to collect ES 
cells is medically desirable because the cells are duplicates of the patient‘s own cells (the 
genotype matches the donated skin cell nucleus), making them less likely to be rejected by the 
body.  But SCNT is also surrounded by large ethical debates because this same process would be 
used in theory to create a reproductive clone.  Many people confuse therapeutic cloning with 
reproductive cloning.  Most people, including our current President Obama, believe reproductive 
cloning is highly unethical, especially the idea of creating humans to provide tissues to treat the 
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person from which the clone was made.  Others argue that therapeutic cloning, once it has been 
achieved in humans, will be a great technique in the field of stem cells and regenerative 
medicine. The Ethics Advisory Board believes that ―therapeutic cloning research has lifesaving 
potential and could dramatically address urgent medical needs‖ (Green, 2008). 
 
Formulating Public Opinions on Stem Cells 
One of the major causes for ethical dilemmas comes not from what people know about 
stem cell research, but rather what they are told about it. In a 2008 poll conducted on the 
knowledge people had about stem cells, only seventeen percent of the poled population had an 
in-depth understanding of the topic (Levin, 2008).  This demonstrates that the vast majority of 
people are formulating their opinions on stem cells without understanding key concepts. The 
source of much of the population‘s knowledge on stem cell research comes from religious information or 
the media. Religion has always gone hand in hand with ethical arguments within science because 
many people base their ethics around their religion. However, as time passes the public is 
becoming more informed on the top stem cells, ―Three years ago, Americans were only dimly 
aware of and fairly evenly divided over stem cell research. Since then, support for this research 
has grown among most demographic and political groups‖ (Fact Sheet, 2006). 
Because of the public‘s general lack of knowledge on stem cells, they can more easily be 
influenced on which side of a poll to choose.  Someone casting the poll who favors stem cells 
could pose a question in the form of ―Do you support stem cell research?  Research that could 
cure many diseases such as: Parkinson‘s, Alzheimer‘s, spinal cord injuries, and possibly even 
save lives in the future.‖  That question might lead a person who does not know much about the 
subject matter to support the research.  While on the other hand, a poll performed within the 
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Catholic Church could pose the question ―Do you support stem cell research? Research that 
destroys embryos and potential life.‖  When the question is asked like that, a negative 
connotation is given to stem cell research which could persuade someone to vote against the 
research. Or by not stipulating whether the question specifically pertains only to embryonic stem 
cells, a poll could miss those individuals who actually support research on adult stem cells.  This 
poll swaying does not allow for a very accurate conclusion on voter stance.  
The topic of stem cells is such a controversial topic that it is constantly debated in 
political agendas.  The stance taken by a Politian can drastically affect the political race by 
influencing not only voters but also contributors. Laws and regulations politicians put on stem 
cells affect federal research funds, which are where a majority of scientists get their funding, and 
this topic will be discussed in detail in Chapter-4. 
 
Religious Views on Stem Cells 
When discussing the ethics of stem cells, it is important to understand the views of the 
world‘s major religions. Religion has a deep impact on people‘s views throughout the world, 
giving guidance on what is ethical and what is wrong within that faith. Embryonic stem cell 
research, being the most controversial, focuses on the topic of when life begins. Each religion 
has its own belief as to when life begins, so from that stance we can derive a discussion of 
whether it is permissible to destroy the embryo to retrieve ES cells.  On the opposite spectrum, 
the use of adult stem cells is accepted by all major religions, and encouraged to be continually 
studied to try to save lives.  All major religions also agree that reproductive SCNT must not be 
performed, while grouping therapeutic SCNT with their particular stance on ES cells. 
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Judaism  
 The Judaic religion is in favor of ES cell research because of two important reasons. 
First, in their faith it is believed that the human body is merely a loan from God, and it is their 
duty to find cures for diseases. The second reason is that an embryo is not considered to have life 
until after forty days, and prior to these forty days it is just a mass of cells (Ayon, 2002).  This 
removes the argument of whether ES cell research is ethical because the cells are harvested at 
day five, well before the embryo is considered to have life. ―Our bodies belong to God; we have 
them on loan during our life. God, as owner, can and do impose conditions on our use of our 
bodies. Among those is the requirement that we seek to preserve our life and health‖ (Dorff, 
2001). Rabbi Dorff, a professor of Jewish theology at the American Jewish University, interprets 
both Judaic law and theology, and explains the obligations of the followers to protect the body.  
The pursuit of curing disease to protect the body makes ES cell research mandated by the faith. 
The use of SCNT as a source for therapeutically cloned ES cells is also approved in the Judaic 
religion because it is furthering the pursuit of healing. The one stipulation in dealing with this 
method is that the cloned stem cells must be used for therapeutic reasons only, not reproductive 
cloning. (Samber, 2001) 
 
Hinduism 
 The Hindu religion does not report to one central source, making the exact stance of all 
Hindu followers undeterminable. The sources of information on Hindu ethics of stem cell 
research come from various Hindu scholars speaking on their interpretation of beliefs. ―In 
traditional Hindu belief, conception is the beginning of a soul‘s rebirth from a previous life. 
Some Hindu traditions place the beginning of personhood between three and five months of 
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gestation, while few believe that the soul‘s rebirth can occur as late as the seventh month‖ 
(Knowles, 2010). This wide variety of defining when life actually begins does not give a clear 
opinion to formulate the Hindu ethical stance on stem cell research. However, another source 
from which to draw a conclusion is to look at Hindu stance on abortion. ―Destruction of an 
embryo could still be justified if it is considered to be an "extraordinary, unavoidable 
circumstance" and an act "done for greater good"‖, says Swami Tyagananda, Hindu chaplain at 
the MIT Religious Activities Center in Cambridge, Massachusetts (Reichhardt et al., 2004). The 
Hindu debate then comes down to whether stem cell research is for the greater good, curing 
diseases and saving lives.  
 
Buddhism  
 Buddhism also does not have a central authority to state its religious opinion on stem cell 
research.  There is no teaching within Buddhism that directly articulates the morality of the 
research, making it difficult to document whether Buddhists support stem cell research.  
The Buddhist religion places great importance on the principle of ahimsa, or non-
harming, and therefore has grave reservations about any scientific technique or 
procedure that involves the destruction of life, whether human or animal... 
Buddhism teaches that individual human life begins at conception. By virtue of its 
distinctive belief in rebirth, moreover, it regards the new conceptus as the bearer 
of the karmic identify of a recently deceased individual, and therefore as entitled 
to the same moral respect as an adult human being (Davis et al.,2006). 
 
This interpretation of Buddhist beliefs shows a general disposition for doing no harm, so even 
though stem cell research potentially saves lives, the cost of harming living things to get there is 
not acceptable.  This also includes the use of SCNT to obtain ES cells, because it also destroys 
an embryo. The only acceptable method in the Buddhist religion is the use of adult stem cells 
because there is no destruction of life. (Holmes, 2004) 
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Christianity 
 Christianity is made up of many faiths, such as Catholic, Orthodox, and Protestant 
Churches.  The Christian faith generally teaches that the life begins at conception, and the 
embryo has a soul, so it must be treated as a human being. The Catholic Church is the most clear 
Christian religion on the topic of ES cell research, with the Pope making direct statements on the 
topic.  "When human beings in the weakest and most defenseless state of their existence are 
selected, abandoned, killed or used as pure 'biological material,' how one can deny that they are 
being treated not as 'someone' but as 'something?'‖ (Pullella, 2008). This quote comes from Pope 
Benedict in an address to members of the Vatican department on doctrinal matters, 
demonstrating his strong displeasure with ES cell research. This matter is of high importance to 
the Catholic Church even though there is no direct link to passages in the Bible that demonstrate 
when life begins, making it hard to derive the church‘s stance from the Bible. The stance from 
the Catholic Church towards ES cell research is that it relies on the destruction of some 
defenseless human beings for the possible benefit of others (Fastiggi, 2010). The form of stem 
cells research that is approved by the Catholic Church is adult stem cells.  Pope Benedict XVI in 
2008 approved of this method of stem cell research giving it an ethical approval in an article 
form Catholic.org ―Adult Stem Cell research is fully supported by the Catholic Church. In fact, 
the Church is helping to fund it‖ (Deacon Keith Fournier, 2010). 
 The Methodist church, a branch of Christianity, is not as strict when it comes to 
embryonic stem cell research.  Many of the core beliefs are about the same about the embryo 
having life and needing to be treated with respect and dignity; however there is a place for the 
acceptable use of embryos for research. ―Given the reality that most, if not all, of these excess 
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embryos will be discarded—we believe that it is morally tolerable to use existing embryos for 
stem cell research purposes‖ (United Methodist Church, 2004). This instance of using embryonic 
stem cells is only tolerable because the research is for the benefit of mankind.  So within very 
extensive global religions, such as Christianity, different stances on stem cells can exist. 
 
Islam  
 The Islamic faith is guided by two sources of law, The Qua‘ran and the Shari‘ah.  But, 
from these two documents of the history of the religion there is no direct discussion about 
embryos or life. The interpretation from the Qua‘ran is that life begins when ensoulment, the 
breathing of Allah‘s spirit into the fetus, takes place. There is a difference in opinion whether this 
takes place at forty days or one hundred and twenty days from conception, depending on one‘s 
interpretation of the Qua‘ran (Fadel, 2007), but in either case it is well after five days after 
conception, so deriving ES cells is not considered destroying a life.  The following is a translated 
interpretation of religious opinion from the Muslim world league‘s Islamic Jurisprudence 
Council conference in December 2003. 
It is permissible to acquire, grow and use stem cells for therapy or scientific research as long as the cells’ 
sources are permissible. Examples of permissible sources are adults who consent as long as it does not 
inflict harm on them, children whose guardians consent for a legal benefit without inflicting harm on the 
children, placenta or umbilical cord blood with the permission of the parents, spontaneously aborted 
embryos or those aborted for a legally acceptable cause and with the permission of the parents, and excess 
fertilized eggs produced during the course of IVF and donated by the parents with assurance that they are 
not to be used to produce an illegal pregnancy. It is forbidden to obtain or use stem cells if its source is 
forbidden. Examples of this include fetuses intentionally aborted without a legal medical reason, 
intentional fertilization between a donated ovum and sperm (Fadel, 2007). 
 
This statement gives a very precise stance on stem cell use from a high official within the Islamic 
faith.  Stem cell research is allowed as long as other forbidden laws of faith are not violated at 
the same time, and the research is going to benefit the good of mankind. The use of SCNTs is 
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permitted because it strives to achieve benefits for the greater good, as long as it stays away from 
reproductive cloning.  
 
iPS Cell Ethics 
Induced pluripotent stem (iPS) cells were first produced from humans in 2007 (Takahashi 
et al., 2007) and this brought forth a new direction in stem cell research.  As discussed in 
Chapter-1, iPS cells are an alternative to using ES cells derived from fertilized embryos, and 
open new paths for research in stem cells.  iPS cells are pluripotent cells induced to a de-
differentiated state by treating an adult cell (such as a skin fibroblast cell) with a combination of 
transcription factors to induce the change to the ES-like state.  iPS cells are less controversial 
than embryo-derived ES cells because no embryo is destroyed.  Being able to stray away from 
having to use embryonic stem cells allows scientists to remove themselves from controversy 
because there is no destruction of the potential life.  The discovery of iPS cells hopefully creates 
another alternative to using ES cells, but it is critical for scientists to prove that iPS cells are as 
medically potent as ES cells.  iPS cells also provide less chance of immune rejection than ES 
cells because the cells are created from the patient‘s own body.  After the initial announcement 
of the first human iPS cells, President George Bush‘s Press secretary released, ―By avoiding 
techniques that destroy life, while vigorously supporting alternative approaches, President Bush 
is encouraging scientific advancement within ethical boundaries" (Ertelt, 2007). This new 
technique has even shown light to President Bush, someone who was strongly against using ES 
cells.  
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Chapter-3 Conclusion 
 The topic of stem cell research will always be surrounded by an ethical debate because it 
is on the forefront of science, and it is still being determined as to what is capable from this 
research.  Embryo research was started in the 1960‘s with the application of IVF to humans, and 
since then has gone through many stages and developments.  The hope is that the research will 
lead to cures for major diseases, but for this to happen research must be strongly supported.   
 Although some religions feel working with ES cells is unethical, this author feels that 
sacrificing something that is smaller than the tip of a needle to cure diseases is well worth it.  
With respect to the source for embryos, the use of excess IVF embryos originally created for 
reproductive purposes is the most logical place to begin.  Now that those excess embryos are no 
longer needed, they should be used to save lives in the future.  If those embryos become 
depleted, then the author of this chapter believes IVF embryos should be created solely for 
research purposes, with donor consent. To this author, it does not matter whether the embryos 
come from reproductive IVF clinics or are created in a lab solely for research, it is important to 
have these embryos to continue ES cell research. 
With respect to adult stem cells (ASCs), medical progress has already been shown with 
these cells, but the downside to using them as the sole source of stem cells is their capabilities 
are not as vast as ES cells.  They are hard to isolate and grow.  So this author feels that ASCs 
should be used to treat specific diseases when their potency proves high enough, and if not ES 
cells should be used. 
Induced pluripotent stem (iPS) cells are the biggest discovery in the past decade of stem 
cell research. These cells appear to be pluripotent, and could provide a replacement for ES cells 
derived from fertilized embryos, but more research must be done to prove their potency.  iPS 
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cells remove the ES cell controversy, and allow researchers to concentrate on moving forward 
with their work.  If iPS cells eventually prove to be as potent as ES cells, the author believes ES 
cells may become phased out based on their negative ethical associations. 
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CHAPTER-4:  STEM CELL LEGALITIES 
 
Clinton Biltucci  
 
 
 
Introduction 
 Beyond the ethical and moral issues associated with controversial stem cell research lie 
the laws that regulate the research.  The use of embryonic stem (ES) cells is highly debated due 
to the demolition of an in vitro fertilized (IVF) blastocyst embryo used to isolate the cells.  Thus, 
the laws regulating ES cell research focus on embryos and embryo research.  Can embryos be 
used for research purposes?  If so, who pays for it?  Must the embryos come from IVF clinics 
where they were initially created for reproductive purposes?  Can embryos be created solely for 
research purposes?  Must donor consent be required to obtain an embryo?  Each country must 
deal with these questions.   
 Since the advent of IVF in the late 1960‘s, the topic of embryo research has been highly 
contested in the United States.  Americans have seen both progression and regression in the 
research and use of stem cells through different presidential terms in the past few decades.  And 
stem cell research is a major issue that has influenced American voters in the past presidential 
elections.  Not only is this a domestic issue, but many countries throughout the world have 
created stem cell policies.  This chapter will document some of the U.S. and international 
policies on embryos and stem cell research. 
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U.S. Presidential Stem Cell Policies 
 
Early U.S. Embryo and Stem Cell Policies 
 In the late 1960‘s, IVF procedures were first applied to humans.  These clinics produce 
fertilized embryos for reproductive purposes, but not all of the embryos are used.  This creates 
excess embryos, and fierce debates have since ensued whether these excess embryos can be used 
for research.  Moreover, in 1973, the Supreme Court decision on Roe vs. Wade (Vestal, 2008) 
legalized abortion, and the decision subsequently brought forth a stronger debate concerning the 
research of tissues isolated from aborted fetuses.  Fearing women would be encouraged to have 
abortions to create tissues for research, Congress decided not to fund embryo research or to allow 
research on aborted tissues (Wertz, 2002).  Thus began the never ending controversy that still 
surrounds embryo and stem cell research to this day. 
 In 1974, President Nixon‘s National Commission for the Protection of Human Subjects of 
Biomedical and Behavioral Research recommended a ban on all federally funded research using 
embryos and fetal tissues, and the ban was enacted by congress.  Although President Ford in 
1975 initially appointed an Ethics Advisory Board to make recommendations on embryo and 
fetus research, in 1981 President Reagan ended the ethics board‘s charter, allowing the original 
1974 ban to remain in effect (Stem Cell Tracker, 2009).  
 
President Clinton’s Stem Cell Policies (1993-2001) 
 President Clinton was a great supporter of stem cell research.  It can be said that much of 
the former President‘s support stemmed from a friendship with the former chief of staff Erskine 
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Bowles.  President Clinton made his views apparent on stem cell research with the following 
statement: 
 Diabetes afflicts two children of my friend and former chief of staff Erskine Bowles, as 
 well as millions of other Americans, with a disproportionate impact on our minority 
 population. When I became President, I learned that diabetes and its complication 
 account for a staggering 25% of all Medicaid costs. That's a big reason why, as President, 
 I supported stem cell research (Clinton, 2004). 
 
  In January 1993, newly elected President Clinton reversed the original 1974 ban on fetal 
tissue research by passing the National Institute of Health Revitalizations Act.  This act allowed 
the National Institute of Health (NIH) to fund human embryo research (Dunn, 2005).  A year 
later, recommendations came forth from the NIH Human Embryo Research Panel, which was 
created by Clinton to examine both moral and ethical issues surrounding stem cell research.  One 
recommendation included the use of spare embryos from fertility clinics as a source of tissue for 
research, and as a source for deriving ES cells.  Although many scientists viewed these 
recommendations as valid because no new embryos would be created or used only for research 
purposes (they would be initially created only for reproductive purposes), the recommendations 
created an uproar.  Within a year, Congress banned the use of federal funds for any experiment 
in which a human embryo is either created or destroyed by any means, including for reproductive 
purposes (Dunn, 2005).   
 Later in 1998,  the first human embryonic stem cell lines were created (Thomson et al., 
1998).  This was a major scientific achievement that provided hope for treatment of conditions 
such as Parkinson‘s, heart disease, and diabetes.  Director of the NIH, Harold Varmus stated 
―This research has the potential to revolutionize the practice of medicine‖ (Dunn, 2005).  
However, with the congressional ban still in place, no federal funds could be used to support ES 
research, so this new human ES research was funded by private institutions. 
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President Bush’s Stem Cell Policies (2001-2009) 
 Stem cell research experienced a deep delay beginning in 2001 due to new laws and 
legislation that came forth during the Bush administration.  In his State of the Union address, 
President Bush was quoted saying, ―...no human life should be started or ended as the object of 
an experiment‖ (Agnew, 2003).  In 2001, new legislation in both the House and Senate was set in 
place.  First a law was enacted to ban the use of somatic cell nuclear transfer.  This was a type of 
cloning technique used to create a living human organism that  had only been used on sheep in 
the past.  And with respect to human embryos, President Bush announced that scientists who 
received federal research funds could only work with ES cell lines derived prior to August of that 
year (Agnew, 2003).  As President Bush said: 
 ―I‘m a strong supporter of adult stem cell research, or course.  But I made it very clear to 
 the Congress that the use of federal money, taxpayers‘ money, to promote science which 
 destroys life in order to save life is -- I‘m against that.  And therefore, if the bill does that,  
 I will veto it.‖  (Baker, 2005) 
  
 The Bush August 2001 ban on federal funding to derive new ES cell lines severely 
limited the total number of lines available to researchers.  Although initially the number 
appeared to be near 100, several lines quit growing, some were determined to be genetically 
identical, and others were unable to differentiate, so the final number was more like 20 (Holden 
and Vogel, 2002; Rowley et al., 2002; Abbott et al., 2006; Ford, 2006).  In 2004, President Bush 
received a letter sent from 58 Senators, including 14 Republicans, pleading to expand the number 
of stem cells lines that could be used experimentally for federal funded research (Dunn, 2005).  
These Senators believed that the restrictions made by the Bush administration were stunting 
medical advances.   
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 Although in 2006, the Senate voted to loosen restrictions that President Bush had placed 
on stem cell research, President Bush vetoed the bill (Bash, 2006).  ―The bill, which the Senate 
passed....would have loosened the restrictions on federal funding for stem-cell research‖ (Bash, 
2006).   President Bush believed the bill would support taking innocent human life in hope of 
discovering medical benefits for others (Babington, 2006).  During his administration, Bush 
would go on to veto yet another bill proposed by the Senate, claiming that stem cell research was 
unmoral due to human embryos being destroyed.   
  
President Obama’s Stem Cell Policies (2009-Present) 
 In March 2009, newly elected President Barack Obama signed an executive order in 
which researchers could apply for grant money to study some of the hundreds of cell lines that 
were derived from private funds under the Bush administration, and would now become 
available (Childs and Stark, 2009; Hayden, 2009; Wilson, 2009).  The funding to support ES 
research will come from ‗Challenge‗ grants, which will be funded by the economic stimulus 
package (Kington, 2009).  Obama‘s executive order removed the 2001 restrictions set in place 
during the Bush administration and expanded NIH support of human stem cell research.   Under 
this order, the Secretary of Health and Human Services may conduct scientifically worthy human 
stem cell research, including human embryonic stem cell research (Kington, 2009).  As President 
Obama stated: 
 ―In recent years, when it comes to stem cell research, rather than furthering discovery, 
 our government has forced what I believe is a false choice between sound science and 
 moral values.  In this case, I believe the two are not inconsistent‖  (Wilson, 2009). 
 
 President Obama‘s views on stem cells are evident.  ―At this moment, the full promise of 
stem cell research remains unknown, and it should not be overstated‖ (Childs, 2009).  It is 
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Obamas‘s hope that the United States will soon become one of the world‘s leading nations 
within the field, and enhance the contribution of America‘s scientists in important new 
discoveries that will benefit humankind.  Obama stated: ―We will vigorously support scientists 
who pursue this research.  And we will aim for America to lead the world in discoveries it one 
day may yield‖ (Hayden, 2009).  However, even with the new order, President Obama was clear 
this would not open the door to human reproductive cloning when he stated: 
 ―We will develop strict guidelines, which we will rigorously enforce, because we cannot 
 ever tolerate misuse or abuse.  And we will ensure that our government never opens the 
 door to the use of cloning for human reproduction.  It is dangerous, profoundly wrong, 
 and has no place in our society, or any society‖ (CBS/AP, 2009). 
  
 The transition from the Bush administration to the Obama Presidency has seen an 
increase in the number of available ES cell lines.  Estimates of these new lines range from 400 to 
1,000 since President Bush cut federal funding for stem cell research in 2001 (Hayden, 2009).  
The significance of many of these new lines is that they were derived from embryos that had 
genetic predispositions to specific diseases, so these lines could be more relevant to disease 
research (Hayden, 2009). 
 Obama‘s 2009 executive order also called for the NIH to develop guidelines and 
regulations to govern federally funded human embryonic stem cell research.  The NIH titled 
these guidelines the ―National Institutes of Health Guidelines for Human Stem Cell Research‖ 
(Federal Register, 2009).  These guidelines were initially published in preliminary form, but 
were later released in a more finalized form (Holden, 2009).  The guidelines are based on two 
main principles.  The first being that research with human embryonic stem cells has the potential 
to improve our understanding of human health and illness, and discover new ways to prevent 
and/or treat illness.  Thus, the guidelines favor working with ES cell lines.  The second guiding 
principle states that individuals donating embryos for research should do so freely, with 
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voluntary and informed consent (Kington, 2009).  The guidelines are divided into several 
sections that apply specifically to embryos donated in the United States or obtained from foreign 
countries.   
 Section I consists of a scope of the guidelines.  Section II describes the conditions and 
review processes for determining human embryonic stem cell eligibility for NIH funds (Kington, 
2009).  A controversial part of this section is the mandate to obtain embryos only from IVF 
clinics where the embryos were originally created for reproductive purposes, and with donor 
consent.  Many scientists wanted NIH to recommend creating embryos for research purposes, as 
currently allowed in some countries, but NIH went with the more conservative stance.   Section 
III is brief, but describes the use of NIH funds to support stem cell research.  Sections IV and V 
describe research that is not eligible for NIH funding, such as inserting primate ES cells into 
blastocysts for implantation to alter the germ line (Kington, 2009).  Section V includes two 
subsections.  The first states that NIH funding is prohibited in reference to the derivation of ES 
cells from human embryos in accordance with the Omnibus Appropriations Act (Kington, 2009).  
The second rejects NIH funding for human ES cells derived from other sources such as somatic 
cell nuclear transfer, parthenogenesis, and/or IVF embryos created solely for research purposes 
(Kington, 2009).  It is the job of the NIH to review and update these guidelines periodically.  
One recent recommendation is that donor consent be obtained at the time of sperm and egg 
donation, not afterwards at time of embryo usage (Lo et al., 2010). 
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Individual State Funding of Stem Cell Research 
California 
 California did not get to where they are today without controversy.  In 2002, the 
International Society for Stem Cell Research (ISSCR) was formed.  This is an independent, 
nonprofit organization that was created to exchange information on stem cell research.  That 
same year, California was declared to be a ―restriction-free zone‖ (allowing them to work with 
ES stem cells) by then acting Governor Gray Davis (Scott, 2006).  The zoning law allowed 
therapeutic cloning and embryo research, but banned reproductive cloning (Scott, 2006).   
 In 2004, California voters approved Proposition 71, a 10 year, 3 billion dollar funding 
program for stem cell research (Vestal, 2008).  This placed California ahead of the federal 
government and many other nations in promoting stem cell research.  In 2005, scientists in 
California were able to help partially paralyzed mice walk again (Palca, 2007) by injecting 
human neural stem cells into the spinal cords of the mice.  When the California stem cell funding 
stalled in 2006, Governor Schwarzenegger provided a state loan of 150 million dollars.  ―This is 
why we are not waiting for anyone to do it for us, we are creating the action right here in 
California,‖ said Schwarzenegger (Palca, 2007).  California is also noted for its biotech industry 
where nearly 11% of the country‘s biotech scientists work.   
 
New Jersey 
 New Jersey became the first state in 2004 to actually appropriate state funding for stem 
cell research.  A reported 10 million dollars in funds was to be distributed over 10 years to 
university, non-profit, and commercial labs in the state (Vestal, 2009).  In 2006, governor Jon 
Corzine signed a bill to establish several stem cell research facilities in New Jersey.  A reported 
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150 million dollars was spent to establish the Stem Cell Research Institute of New Jersey (Vestal, 
2009).  In 2007, the New Jersey Commission of Science and Technology (NJCST) awarded more 
than 10 million dollars in stem cell research grants.  Of this 10 million, 5.5 million dollars was 
given to two core facilities, and the remaining was awarded in individual grants (The 
Commission, 2007). 
 
Massachusetts  
 In 2007, Massachusetts Governor Deval Patrick proposed 1 billion dollars in state 
funding for biomedical research (Estes, 2007).  Half of this money would be used to establish a 
research center that would house the nation‘s largest embryonic stem cell bank.  And 
Massachusetts legislators added two new sections to the statutes on stem cell research.  The first 
would create an institute for stem cell research and regenerative medicine at the University of 
Massachusetts; 1,000,000 dollars was to be spent on the stem cell biology core alone (National 
Conference of State Legislatures, 2008).  The second section would grant a reported 10 million 
dollars in funds to create a life sciences center that would promote research in advanced and 
applied sciences which includes stem cell research (National Conference of State Legislatures, 
2008).  
 Making this preliminary plan come alive, later that same year the Board of the 
Massachusetts Life Sciences Center (MLSC) voted to approve more than 8.2 million dollars in 
funding to the University of Massachusetts Medical School (UMMS) (Worcester) (Shelton, 
2007).  The money was used to establish the Massachusetts Human Embryonic Stem Cell (hESC) 
Bank and an Iternational Massachusetts hESC Registry (Shelton, 2007).  The Massachusetts 
hESC Bank serves as an international repository of human ES cells derived from all over the 
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world, while the hESC Registry promotes efficiency in human ES cell research and the 
disbursement of the hESC lines.  
  
International Stem Cell Policies 
 In 2002, German Parliament voted to allow the import of ES cells for scientific research 
(Kim, 2002).  This decision drew much criticism from Germany‘s Catholic and Protestant 
Churches who believed that Parliament‘s decision threatened the ―protection of human life from 
the moment of conception‖ (Kim, 2002).  Today, Germany remains one of the more conservative 
states in Europe in forbidding the derivation of any new human ES cell lines.  New hESC lines 
can be imported for research in Germany, however importation is only permitted under strict 
conditions (Hoffman, 2005). 
 Japan is a very liberal nation when it comes to hESC research.  Policies regarding the 
research of human ES cells not only allow research on supernumerary embryos, but also on 
embryos created specifically for research (Ritter, 2009).  Japan also allows scientists to conduct 
somatic cell nuclear transfer (Ritter, 2009).  England, Sweden, China, and Israel are also 
countries that strongly support ES cell research. 
  
Chapter-4 Conclusion 
 After researching the legal issues surrounding human ES cell research, I truly believe that 
the government should fully back this new technology.  In the United States, the funding 
available for ES cell research has been tied directly to the President in office at the time.  Our 
country experienced a period ES cell prosperity during the Clinton administration, but foundered 
during the Bush administration.  Under President Obama, our country now has started taking the 
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right steps to federally fund ES cell research.  I believe that the level of ES cell scientific success 
in our country has come at the mercy of the President in office at the time.  I believe that the 
strong support of government is crucial for the advancement of science, and this is exactly what 
scientists need to make medical advances to improve life. 
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PROJECT CONCLUSIONS 
 
 
The authors of this IQP project believe that it is acceptable to work with ES cells 
considering the number of medical applications that can be used to benefit society.  However, 
there are still many obstacles that inhibit the growth of stem cell research, including political and 
moral debates, lack of funding, and scientific technical barriers that still need to be crossed 
before more clinical advances can be accomplished.  We believe the potential benefits that can 
be obtained through the use of stem cells in applied medical therapies, such as Parkinson‘s 
Disease, heart attacks, and diabetes, are too great to ignore.  
As for an acceptable source of embryos to derive ES cells, the authors believe ES cells 
may be derived from unused IVF embryos originally created for reproductive purposes, or from 
paid egg donors.  We believe that the 5-day IVF embryo is not yet a full human being when ES 
cells are removed, rather it is a mass of cells with the potential to develop into a human.  
Although our research documented that some people believe ES cell research to be immoral 
when life begins at conception, we acknowledge both sides of the argument but believe that ES 
cell research is about benefiting human life in the most therapeutic and practical ways possible. 
Induced pluripotent stem cells (iPSCs) and adult stem cells (ASCs) are a great alternative to the 
moral issue that surrounds ES cells, and these cells should be used whenever possible, but the 
focus of stem cell research should ultimately be devoted to ES cells as they are the most 
powerful to benefit patients.  
However, a line needs to be drawn as to how far this research will take us in terms of 
reproductive cloning (cloning entire human beings), and so the authors agree with all countries 
that have currently banned reproductive cloning.  With respect to other stem cell policies, our 
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group members agreed most with England‘s policies, arguably the most liberal nation.  Japan is 
also another nation with legislation that permits the research on ES cells and also allows SCNT.  
The main reason our group chose these countries is due to the availability of federal funding.  
Once group member accredited Japan and England‘s strong stem cell scientific progress to the 
strong federal funding in both nations.  Everyone agreed that our government should provide 
more federal funding for ES stem cell research. 
The study of stem cells is progressing at an exponential rate, but should always be used 
for the good of mankind. This means that the patient in need of medical care will receive the 
most efficient and therapeutic techniques possible, regardless of the source of stem cells needed 
to obtain these results. 
 
